Umecrine Cognition attends the JP Morgan 42nd Annual Healthcare Conference 2024 in San Francisco

STOCKHOLM – January 8, 2024. Umecrine Cognition today announces that the company will attend the JP Morgan 42nd Annual Healthcare Conference in San Francisco, USA. The event takes place January 8-11th 2024, gathering companies, organizations, and financial institutions in the life science sector from around the world.

“We are looking forward to meeting with potential future partners at the JP Morgan’s Annual Healthcare Conference. This year we attend with a strong foothold based on new preclinical insights pointing toward golexanolone’s potential to dampen neuroinflammation, a common molecular pathway implicated in primary biliary cholangitis (PBC), hepatic encephalopathy (HE) and Parkinson’s disease, but it is also common in other disabiliting peripheral and CNS related disorders and conditions. Golexanolone has in our studies normalized GABA signalling resulting in a significant decrease in both neuropsychiatric and motoric symptoms. These results give way for treatment in several new diseases where neuroinflammation is pivotal. Furthermore, our Phase 2 study in PBC targeting patients with severe fatigue and cognitive impairment is running in Europe during 2024 , and we look forward to discussions with resourceful actors in this treatment area,” says Anders Karlsson, CEO of Umecrine Cognition.

For further information, please contact:

Anders Karlsson, CEO, Umecrine Cognition AB
Phone: +46 70 – 918 00 10, e-mail: [email protected]

About Umecrine Cognition AB

Umecrine Cognition AB develops a completely new class of pharmaceuticals against neurological disturbances in the brain that may arise as a consequence of several underlying diseases, leading to strongly reduced cognitive functions and wakefulness. Results from an internationally recognized clinical Phase 2 study indicates that the company’s most advanced drug candidate, golexanolone, normalizes the brain’s signaling and improves cognition as well as wakefulness in patients diagnosed with hepatic encephalopathy. The continued drug development will initially focus on patient groups whose symptoms arise from chronic liver diseases. The mode of action is however relevant in a number of other indications. For more information, visit